On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.
Shaked
Yuval
Y
Bertolini
Francesco
F
Emmenegger
Urban
U
Lee
Christina R
CR
Kerbel
Robert S
RS
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D017209:Apoptosis / Q000187:drug effects; D014408:Biomarkers, Tumor / Q000097:blood*; D051929:CD146 Antigen / Q000378:metabolism; D017321:Clinical Trials, Phase I as Topic; D004334:Drug Administration Schedule; D042783:Endothelial Cells / Q000187:drug effects* / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D051929:CD146 Antigen; C497902:MCAM protein, human; C455219:N-acetylcochinol-O-phosphate; D009943:Organophosphorus Compounds